Insights and Best Practices in IP – Life Sciences Field | 2026 Report
How leading life sciences IP teams are adapting to complexity, risk, and rapid change.
👉 Download the full report to access detailed insights, practitioner perspectives, and best practices shaping IP strategy in life sciences today.
The life sciences IP function is under increasing pressure. Shorter innovation cycles, regulatory divergence, geopolitical uncertainty, and crowded competitive landscapes are forcing IP teams to operate with greater strategic foresight and commercial alignment than ever before.
This Insight IP research report draws on in-depth interviews with senior IP leaders at life sciences companies across Europe, offering a real-world view of how IP strategy is evolving in practice not theory.
Inside the report, we explore how organisations are managing IP across the full product lifecycle, from early-stage innovation and patent filing through to enforcement, litigation, and monetisation.
What you’ll learn
- How IP teams are aligning more closely with R&D and commercial leadership to support faster, better-informed decision-making
- The practical challenges of managing global IP portfolios across divergent jurisdictions and regulatory regimes
- How leading organisations are prioritising filings, maintenance, enforcement, and spend under resource and budget constraints
- The growing role of monitoring, analytics, and AI in competitive intelligence and enforcement strategy
- How the UPC, geopolitical change, and jurisdiction-specific rules are reshaping litigation risk and opportunity
- Best practices for valuing, monetising, and future-proofing IP assets in a volatile market
Who this report is for
- Heads of IP, Chief IP Counsel, and IP Directors
- In-house legal teams within pharma and biotech organisations
- R&D and strategy leaders involved in portfolio and product lifecycle decisions
- External counsel advising life sciences clients on IP strategy and disputes
Why Insight IP
Insight IP operates at the intersection of intellectual property, regulation, and complex disputes in the life sciences sector. We support pharmaceutical and biotech organisations with specialist legal and scientific translation, interpreting, document review, and litigation support – and regularly publish research grounded in real client experience.
This report is the first in an ongoing interview-based research series examining how IP strategy is changing across life sciences.
